We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




New Rapid Molecular Test Detects Bacteria and Viruses With 93.33% Accuracy

By LabMedica International staff writers
Posted on 28 Sep 2023

In March of 2020, the World Health Organization declared that SARS-CoV-2, commonly known as the coronavirus, had reached pandemic status. More...

Since that time, close to six million lives have been lost, and approximately two million new infections are being recorded globally each day. To manage outbreaks like COVID-19, which have a huge impact on both public health and the worldwide economy, there is a need for diagnostic tools that are quick, reliable, sensitive, and easily accessible. Scientists have now developed a new molecular test that can detect various bacteria and viruses, including SARS-CoV-2, setting the stage for better preparedness for future pandemics.

A research team at the University of Surrey (Surrey, UK) has developed a new molecular test, called ‘Electro-chemical LAMP’ (eLAMP). This test is not only affordable and rapid but also highly sensitive and can be administered either at home, in a general practitioner's office, or in a hospital lab. eLAMP shares the sensitivity of laboratory-based PCR tests, and when paired with a smartphone, can easily be conducted at home. The test converts the output of another PCR-like test known as LAMP into a simple electric current.

The device used for this electrochemical test is already quite small, and the research team plans to make it even more compact equivalent to the size of a memory stick that can be controlled through a smartphone app. This would enable patients to carry out the test at home and promptly send the results to healthcare services, aiding in monitoring the spread of infections. Additionally, the patients would receive immediate medical guidance. The test, when used on human blood, saliva, and nasal and throat swabs, demonstrated a detection accuracy of 93.33%. It also works efficiently at room temperature, generating results in just 45 minutes.

"A key lesson we took from the COVID-19 pandemic is how crucial rapid, effective and cheap diagnostic tools that can be used at home are to monitoring and containing infectious diseases,” said Professor Johnjoe McFadden, corresponding author of the study and Professor of Molecular Genetics at the University of Surrey. “Our test meets these criteria and can detect lower amounts of the SARS-CoV-2 virus compared to other home-based tests. We are looking for commercial partners to further develop the test and take it to market."

"SARS-CoV-2 is likely to be around for a long time and, unfortunately, new difficult viruses are likely to emerge,” added Dr. Khushboo Borah Slater, co-author of the study from the University of Surrey. “It's crucial to keep working on better ways to test for the coronavirus, and our goal is to further develop our test so that it can be easily used everywhere to help control the disease and prevent future outbreaks."

Related Links:
University of Surrey 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Hematology Consumables
Bioblood Devices
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
image Credit: iStock

Tumor Budding Grading May Predict Chemotherapy Benefit in Resected Lung Squamous Cancer

Outcomes after resection for lung squamous cell carcinoma (SqCC) vary substantially, and the uneven benefit of adjuvant chemotherapy complicates postsurgical treatment decisions. Pathologic markers that... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.